Ask AI
ProCE Banner Activity

Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC

Podcast

For patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy, treatment selection remains challenging because of aggressive disease biology, high symptom burden, limited survival expectations, and variable access to emerging therapies across Europe. This podcast examines European expert perspectives on the evolving role of TROP-2–directed antibody–drug conjugates (ADCs), including sacituzumab govitecan and datopotamab deruxtecan, with attention to treatment sequencing, reimbursement barriers to recent approvals, toxicity-informed treatment selection, ocular and pulmonary toxicity monitoring, and care team readiness for implementing ADC-based therapy in routine practice.

Released: July 28, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity is intended for oncologists and the multidisciplinary team caring for patients with metastatic triple-negative breast cancer, including advanced practice providers, nurses and nurse navigators, patient navigators, pharmacists, and eye care specialists (ophthalmologists and optometrists). 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret current and emerging clinical evidence for TROP2 ADC–based strategies in immunotherapy-ineligible mTNBC, including implications for first-line and later-line treatment planning

  • Individualize treatment selection and sequencing for patients with mTNBC who are not candidates for immunotherapy, integrating prior therapy exposure, disease burden, comorbidities, toxicity risk, and patient preferences

  • Implement multidisciplinary monitoring, toxicity-prevention, and AE-management pathways for patients receiving TROP2-directed therapy, including timely triage and oncology–eye care coordination when clinically indicated